Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

488
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
488
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Clinical development of cancer vaccines.

Nature medicine·2026
Same author

Social status impacts T-cell responses through synapse strength in the prefrontal cortex.

Cell research·2026
Same author

Clinical development of cancer vaccines.

Nature medicine·2026
Same author

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

Nature cancer·2026
Same author

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Nature communications·2026
Same author

Guidelines for T cell nomenclature.

Nature reviews. Immunology·2025
Same journal

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Med (New York, N.Y.)·2026
Same journal

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026
Same journal

Atlas of human brain imaging-derived phenotypes and disease risk.

Med (New York, N.Y.)·2026
Same journal

Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine.

Med (New York, N.Y.)·2026
Same journal

Rethinking parenteral nutrition as supportive therapy for neonatal sepsis.

Med (New York, N.Y.)·2026
Same journal

Power and sample-size estimation in human microbiome research.

Med (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Aug 25, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

740

Next generation T cell therapies for solid cancers.

John B Haanen1, Ton N Schumacher2

  • 1Division of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; Department of Clinical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Med (New York, N.Y.)
|October 15, 2022
PubMed
Summary
This summary is machine-generated.

Researchers enhanced tumor-infiltrating lymphocytes for treating metastatic melanoma by knocking out CISH. This creates a more functional cell product for improved clinical benefit in cancer immunotherapy.

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Related Experiment Videos

Last Updated: Aug 25, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

740
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Tumor-infiltrating lymphocytes (TILs) offer clinical benefit in metastatic melanoma.
  • Current TIL products are poorly defined and have variable antitumor activity.

Purpose of the Study:

  • To develop a more effective TIL product for clinical testing.
  • To enhance the functionality of tumor-reactive T cells.

Main Methods:

  • Knockout of CISH (cytokine-inducible SH2-containing protein) in T cells.
  • Generation of a novel cell product for cancer immunotherapy.

Main Results:

  • Creation of highly functional tumor-reactive T cells.
  • Development of a cell product suitable for clinical testing.

Conclusions:

  • Knocking out CISH is a promising strategy to improve TIL therapy for metastatic melanoma.
  • This approach could lead to more consistent and potent antitumor activity in cancer patients.